$HYFT

The global AI in drug discovery market is projected to grow significantly, with estimates ranging from $160.49B by 2035 (Towards Healthcare) to $13.8B by 2033 (Grand View Research). MindWalk Holdings Corp. (HYFT) appointed Kim Remizowski to its board, emphasizing governance as the company shifts to deploying AI infrastructure in life sciences. HYFT's technology, HYFT®, powers ReefIQ™ and LensAI™ for biological context and reasoning.

MindWalk Holdings (HYFT) launched ReefIQ, pivoting to recurring AI revenue. Q1 FY27 revenue rose 21.3% to C$3.8M, with gross profit up 47.1% to C$2.2M. Operating losses widened 47% to C$6.13M. The company secured a US$30M credit line at 7% and is negotiating enterprise deals for ReefIQ.

MindWalk Holdings Corp. (NASDAQ: HYFT) announced results from a production deployment of the OpenFold3 model with AMD and Vultr, achieving 5x faster antibody-antigen inference. The deployment expands compute capacity for ReefIQ, MindWalk's biological context layer, and validates AIM for OpenFold3 in a production setting. The company aims to reduce costs and onboarding time for enterprise partners.

StoneX reiterated a Speculative Buy rating and $3.00 price target for MindWalk Holdings (HYFT). The company reported Q1 2027 revenue of CAD$3.8M, up 21% YoY, but net loss widened to $6.1M. Analysts predict profitability for fiscal 2027. MindWalk launched ReefIQ and secured a $30M credit facility. H.C. Wainwright also reiterated a Buy rating with a $5.00 target.

MindWalk Holdings Corp. (HYFT) reported a 21.3% revenue increase to $3.8M and gross margin expansion to 58.6% in Q1 2027. The company launched ReefIQ™, its data platform, and secured a $30M credit facility. Net loss widened to $6.1M due to investments in ReefIQ's enterprise rollout. MindWalk is shifting to recurring, platform-based revenue.

MindWalk Holdings Corp. (HYFT) furnished an SEC Form 6-K — earnings release. 99.1 MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027 ReefIQ™ launched commercially, and a US$30 million unsecured credit facility commitment, drawn only as needed, adds balance-sheet flexibility with no dilution. AUSTIN, Texas (S

The global AI in drug discovery market is projected to grow from $2.9B to $13.8B by 2033 (Grand View Research) or $43.9B by 2035 (Global Market Insights). MindWalk Holdings (HYFT) secured a $30M unsecured credit facility at 7% interest, avoiding dilution and asset liens. The company aims to fund operations without issuing equity, protecting its BioIntelligence infrastructure.

MindWalk Holdings Corp. (NASDAQ: HYFT) secured a binding commitment for a $30 million unsecured credit facility from Sanabil (Cayman). The facility has a 7.00% fixed interest rate, a 36-month term, and no equity dilution. Funds will support biologics programs and commercial expansion. The agreement is expected to close within 60 days.

MindWalk Holdings Corp. (HYFT) reported a 46% revenue increase to C$15.6M, with improved margins and narrowed losses. The company focuses on AI-enabled drug discovery, emphasizing its data and systems of record. Comparatively, Veeva Systems (VEEV) rose after strong earnings, while Certara (CERT) and Recursion (RXRX) fell due to missed expectations, highlighting market preference for proprietary data.

MindWalk Holdings Corp. (Nasdaq: HYFT) says its Bio-Native AI platform identified a conserved influenza biological signature that remains consistent despite major viral genetic changes. The company demonstrated ReefIQ on AMD Instinct accelerators at AMD’s Advancing AI 2026 event on July 23, 2026. MindWalk is shifting from platform-only to building pipeline assets and reports LensAI has contracted recurring arrangements.